Phaseline

Companies › Veloxis Pharmaceuticals

Veloxis Pharmaceuticals: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 2; Genitourinary; next expected readout Oct 2028.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
VEL-101
CD40-CD154 pathway antagonist (costimulation blockade)
CD40Phase 2Transplantation, KidneyOct 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07290777VEL-101Phase 2Transplantation, KidneyGenitourinaryOct 2028

Targets

CD40 (1)

Companies with the same targets

AbbVie Xencor Genmab RANI Therapeutics Roche Akamis Bio Alligator Bioscience Novartis

Companies built like this

Kira Pharmacenticals (US) Juro Sciences Vifor Fresenius Medical Care Renal Pharma Vaneltix Pharma Tioga Pharmaceuticals

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.